Fig 3. Abatacept enhances the levels of IL-35 and IL-10 producing Bregs in lung tissues and peripheral blood of OVA- sensitized mice.

(A) Percentage of CD19⁺CD138⁺CD1d⁺ cells in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. (B-C) Percentage of IL-35⁺IL-10⁺ Bregs and IL-35⁺ Bregs in the lung tissues of abatacept IN, abatacept IP treated, or OVA challenged mice. (D) Percentage of CD19⁺CD138⁺CD1d⁺ cells in the PBMCs of abatacept IN, abatacept IP treated, or OVA challenged mice. (E-F) Percentage of IL-35⁺IL-10⁺ Bregs and IL-35⁺ Bregs in the PBMCs of abatacept IN, abatacept IP treated, or OVA challenged mice. Lung tissues of 5 mice and PBMCs of 10 mice were used. Two-way unpaired t-test was used to calculate significance. * ***P < 0.001. Events were recorded and analysed by using BD FACSDiva version 8.0.